Research on development of novel oral squamous cell carcinoma treatment with lenvatinib from an immunological perspective

2021 Fiscal Year Final Research Report

• Project/Area Number: 20K18686
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 57060:Surgical dentistry-related
• Research Institution: Asahikawa Medical College
• Principal Investigator: Yajima Yuki 旭川医科大学, 大学病院, 医員 (60867042)
• Project Period (FY): 2020-04-01 – 2022-03-31
• Keywords: 扁平上皮癌 / 分子標的薬 / バイオマーカー

Outline of Final Research Achievements

There was a difference in the antitumor effect of lenvatinib on squamous cell carcinoma in mice between the two species. Gene expression of “a molecule” was significantly higher in tumors that were resistant to treatment. In vitro and in vivo experiments showed results suggestive of an association with the intensity of expression of “a molecule”. In addition, immunohistochemical staining of “a molecule” showed a high rate of staining of tumor tissues, suggesting that it may be useful for pathological diagnosis.

Free Research Field

歯科口腔外科学

Academic Significance and Societal Importance of the Research Achievements

本研究により着目した「ある分子」がさらなる研究により、口腔扁平上皮癌のバイオマーカーとして有用であることが証明されれば、口腔扁平上皮癌患者の診断や代替治療の選択、治療効果判定などへの活用が期待できる。